Trial Profile
Safety and efficacy of tocilizumab for treatment of chronic antibody mediated rejection in pediatric renal transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2018
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 12 Jul 2018 New trial record
- 06 Jun 2018 Results presented at the 2018 American Transplant Congress